Celldex Therapeutics

Celldex Therapeutics

World Rank (Aug-2026)
4755
Market Cap (Aug-2026)
3.294 Billion USD
Market Cap (Mar-08-2026)
1.959 Billion USD
World Rank (Jan-05-2024)
5,438
Market Cap (Jan-05-2024)
2.151 Billion USD
World Rank (Jul-30-2023)
6,490
Market Cap (Jul-30-2023)
1.640 Billion USD
World Rank (Jan-07-2022)
6,911
Market Cap (Jan-07-2022)
1.706 Billion USD
World Rank (Jan-01-2021)
9,588
Market Cap (Jan-01-2021)
0.693 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
CLDX
Employee Count
134
Employee Count as of Date
As on 2021
Headquarters City/State
New Jersey
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
2 Million USD
Annual Operating Income in USD
-287 Million USD
Annual Net Income in USD
-259 Million USD
Annual Results for Period Ending
For year ending December-2025
Total Assets in USD
583 Million USD
Total Liabilities in USD
56 Million USD
Total Equity in USD
527 Million USD
Balance Sheet for Period Ending
As of December-2025
Business Sector
Healthcare
Biotechnology
Company Website
CELLDEX THERAPEUTICS
Yahoo
Yahoo @ Nasdaq
Company Profile

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Its pipeline includes immunotherapies and other targeted biologics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. Headquarters is in USA.

Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances

Share